Survodutide is an investigational dual agonist that pairs GLP-1 with glucagon, a hormone that raises blood sugar rather than lowering it. Putting that in a weight drug reads as an error. It's the whole design, and no regulator has approved it yet.
Survodutide is an investigational dual GLP-1/glucagon agonist, now in Phase 3. It comes from Boehringer Ingelheim and Zealand Pharma. Its Phase 2 obesity trial cut body weight about 19% at the top dose, over 46 weeks.
The glucagon arm is what sets it apart. That arm may also make the metabolic liver disease data matter more to you than the weight data. Survodutide is approved nowhere.
The glucagon arm
Survodutide's place in the class is defined by which second receptor it picked. Tirzepatide added GIP to GLP-1; survodutide added glucagon. Both are dual agonists, and they are not doing the same thing.
Glucagon is usually cast as insulin's opponent, because it raises blood glucose. Adding it to a weight-loss drug looks backwards until you account for the other thing glucagon receptor activation does: drive energy expenditure and hepatic fat oxidation. Paired with GLP-1's appetite suppression, the glucagon arm supplies an “energy out” component that a GLP-1/GIP dual agonist doesn't have.
That's the same logic retatrutide uses, with one fewer receptor. Retatrutide is GIP plus GLP-1 plus glucagon; survodutide is GLP-1 plus glucagon. We read the comparison as close to a controlled experiment on what GIP contributes. The triple-agonist mechanism covers the full picture.
What the trials show
The Phase 2 obesity trial ran 46 weeks with a dose-escalation design. It reported approximately 19% mean body-weight reduction at the top dose. That places survodutide above semaglutide, and around or slightly below tirzepatide.
Read that ordering carefully. A Phase 2 figure and a Phase 3 figure aren't directly comparable, and Phase 2 results systematically regress.
Survodutide's more interesting program may be the liver one. It has been studied in metabolic dysfunction-associated steatohepatitis, where the glucagon arm's effect on hepatic fat oxidation is direct rather than incidental. We'd expect a drug whose second receptor targets the liver to be well positioned for a liver indication.
The tolerability trade. Glucagon agonism buys energy expenditure and generally carries a heavier gastrointestinal burden than GIP co-agonism, which appears to soften GI effects. More mechanism, more side effects: that trade recurs across the class, and it's the same one retatrutide makes at one receptor further out.
Metabolic research compounds
Survodutide isn't stocked. The GLP-1 class compounds that are — the single, dual and triple agonists discussed throughout this article — are in the catalog, each with a batch-matched certificate of analysis.
Where it stands
Survodutide is not approved anywhere. It's in Phase 3 for obesity, with parallel work in metabolic liver disease. It also isn't widely available as a research compound. Unlike retatrutide, it hasn't attracted a large grey market, largely because it's less searched-for and less hyped.
For how survodutide sits against everything else in the class, see our 2026 class comparison.
Frequently asked questions
What is survodutide?
Survodutide is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. It's investigational: Phase 3 for obesity, with additional work in metabolic liver disease.
How much weight does survodutide produce?
Survodutide cut body weight approximately 19% on average at the top dose, in its Phase 2 obesity trial over 46 weeks. That sits between tirzepatide and retatrutide in the class ordering. Bear in mind you're weighing a Phase 2 result against Phase 3 results, which isn't like for like.
How is survodutide different from tirzepatide?
Different second receptor. Tirzepatide pairs GLP-1 with GIP; survodutide pairs it with glucagon. GIP contributes insulin response and appears to soften GI tolerability; glucagon contributes energy expenditure and hepatic fat oxidation.
Is survodutide FDA approved?
No. Survodutide is in Phase 3 and has no approval anywhere.
Metabolic research compounds
Third-party tested research compounds, each shipped with a batch-matched certificate of analysis showing HPLC purity and mass-spec identity — the documentation this site argues you should hold any supplier to.
What to know now
- It is investigational, and now in Phase 3. Boehringer Ingelheim and Zealand Pharma develop it, and no regulator has approved it.
- Phase 2 cut body weight about 19%. That was the top dose, over 46 weeks.
- The glucagon receptor is what separates it. That second arm, not the GLP-1 half, is why its data read differently from the rest.
- Liver disease may matter more than weight. The metabolic liver disease work could end up being the more important readout for this compound.
- The 19% figure comes from Phase 2. Phase 3 is still running, so treat that number as provisional rather than settled.
References
- Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2024). What is the pipeline for future medications for obesity? International Journal of Obesity, 49(3), 433–451. https://doi.org/10.1038/s41366-024-01473-y
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–hormone-receptor agonist retatrutide for obesity — A phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
Survodutide's Phase 2 weight figure is as summarised in the Melson pipeline review rather than read from the primary trial publication, and is reported here as approximate for that reason.